Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04078022 · ClinicalTrials.gov registry record · Phase 2
Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine
A Phase 2 study of Shigella, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT04078022: Completed Phase 2 study of Shigella, sponsored by University of Maryland, Baltimore.
NCT04078022 is a Phase 2 study of Shigella that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 58 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04078022, a Phase 2 study of Shigella, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether SF2a-TT15 (a monovalent synthetic carbohydrate-based conjugate Shigella vaccine) is safe and effective in the prevention of Shigella infection.
Primary Outcome
Count of participants with primary endpoint (Moderate-Severe Shigellosis)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL SF2a-TT15 Shigella Vaccine
- BIOLOGICAL S. flexneri 2a strain 2457T Challenge Agent
Study Locations (1)
Maryland
- University of Maryland, Baltimore, Center for Vaccine Development and Global Health - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-03-02 |
| Est. Completion | 2024-01-25 |
| Phase | Phase 2 |
What the finished NCT04078022 record still lists
NCT04078022 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Shigella appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04078022 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04078022 about?
NCT04078022 is a clinical study titled "Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine". The purpose of this study is to determine whether SF2a-TT15 (a monovalent synthetic carbohydrate-based conjugate Shigella vaccine) is safe and effective in the prevention of Shigella infection.
What is the current status of trial NCT04078022?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2020-03-02. Estimated completion is 2024-01-25.
What conditions does trial NCT04078022 study?
This clinical trial studies the following conditions: Shigella.
What interventions are being tested in trial NCT04078022?
The interventions under investigation include: Placebo (OTHER), SF2a-TT15 Shigella Vaccine (BIOLOGICAL), S. flexneri 2a strain 2457T Challenge Agent (BIOLOGICAL).
Who is sponsoring clinical trial NCT04078022?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04078022 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shigella
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04078022's enrollment target sits among peer trials
58 1135th of 2000 higher than 860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old
RECRUITING · Phase 2
-
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI